Early Detection of Lung Cancer via Blood Test
Author: University of Bonn
Published: 2011/05/16 - Updated: 2026/04/19
Publication Details: Peer-Reviewed, Informative
Category Topic: Lung - Related Publications
Contents: Synopsis - Introduction - Main - Insights, Updates
Synopsis: This research, authored by the University of Bonn, details the identification of more than 480 nucleic acid molecules in blood whose concentrations shift measurably when lung cancer develops - even in its earliest, most treatable stage. The findings, which draw on blood analysis from over 200 smokers using bio-chip technology, point toward a future routine blood screening test capable of returning a result within 24 hours, without the patient showing any symptoms. For patients, caregivers, oncology professionals, and those at high risk due to smoking history or chronic lung disease, this information is highly relevant - early-stage lung cancer can often be treated surgically and, in many cases, cured, yet today fewer than 15% of cases are caught at that stage - Disabled World (DW).
- Topic Definition: Lung Cancer Early Detection
Lung cancer early detection refers to the identification of cancerous or precancerous changes in lung tissue at the earliest possible stage of disease development, before noticeable symptoms appear and before the cancer has spread. Because lung cancer is staged from one to four - with stage one representing localized, often surgically curable disease and stages three and four carrying a very poor prognosis - catching the disease early is widely recognized as the single most significant factor in improving patient survival rates. Early detection methods have historically included imaging technologies such as low-dose computed tomography (CT) scanning, but emerging research now points to blood-based biomarker screening as a potentially simpler, faster, and more accessible alternative that could one day be integrated into routine medical practice.
Introduction
Early Detection of Lung Cancer
Detecting lung cancer early - Researchers in Bonn are laying the foundation for a future blood test.
Main Content
Scientists working with Professor Dr. Joachim L. Schultze have identified over 480 molecules whose concentration in the blood changes when a person develops lung cancer. These molecules are present in the blood cells either in increased or decreased quantities.
"In lung cancer patients, typical patterns which can be detected with a measuring program thus emerge", explains Prof. Schultze.
The molecules are nucleic acids which form in the body when certain genes are transcribed.
The changes in the blood also occur if the tumor is still in a very early stage. In lung cancer, there are four different stages, explains Prof. Schultze:
"The prognosis for patients in stage 3 and 4 is still very poor even today; even with the most modern therapies, the point of death can only be postponed."
Lung cancer in stage 1, on the other hand, can be treated surgically and it can even be cured in many cases.
"Today, however, a tumor is seldom detected so early, namely in only about 15% of all cases. If a simple screening blood test would increase this percentage, a large proportion of lung cancer patients could survive", says Prof. Schultze.
By contrast, to date, over 80% of all lung cancer patients die within two years after diagnosis, since the tumor is already too far advanced.
Screening for Lung Cancer: A Result Within a Day
In the future, a lung cancer screening test may become part of routine practice: The doctor takes a blood sample from his/her patient, and within 24 hours, he knows with a high degree of certainty whether the patient has lung cancer or not even if the patient does not yet have any symptoms.
For many years, the team working with Prof. Joachim Schultze has investigated the blood of over 200 smokers. About half of them had lung cancer; the others were either entirely healthy or suffered from another lung disease.
"It was important to us that a subsequent test not only be able to differentiate lung cancer patients from healthy subjects, but also from persons with chronic lung diseases."
The researchers then examined the research subjects' blood using bio-chips for certain nucleic acids and in doing so, they found the typical patterns.
The researchers are presently planning an analogous but much larger study with ten times as many patients, in order to confirm the results. If the present results prove to be true in such a study, there would no longer be anything standing in the way of developing the blood test to the point of being ready to be put on the market.
Insights, Analysis, and Developments
Editorial Note: Lung cancer remains one of the deadliest cancers in part because it so often goes undetected until it has already reached an advanced stage - a stage at which even modern therapies offer little more than a delay. The research coming out of Bonn is a reminder that the path to saving lives may, in some cases, be as straightforward as a routine blood draw. While the work still requires validation through larger trials, the identification of a reliable molecular signature for early-stage lung cancer is a meaningful step forward - one that, if borne out, could fundamentally shift screening practices and dramatically improve survival rates for a disease that currently claims the lives of more than 80% of diagnosed patients within two years - Disabled World (DW).Attribution/Source(s): This peer reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by University of Bonn and published on 2011/05/16, this content may have been edited for style, clarity, or brevity.